argenx SE (NASDAQ:ARGX) Shares Sold by Atria Investments Inc

Atria Investments Inc lessened its holdings in shares of argenx SE (NASDAQ:ARGX) by 1.0% in the third quarter, according to its most recent filing with the SEC. The firm owned 2,649 shares of the company’s stock after selling 27 shares during the quarter. Atria Investments Inc’s holdings in argenx were worth $1,436,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD boosted its position in argenx by 49.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock worth $2,167,235,000 after acquiring an additional 1,830,651 shares during the period. Janus Henderson Group PLC boosted its position in argenx by 24.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock worth $872,690,000 after acquiring an additional 439,889 shares during the period. Avoro Capital Advisors LLC lifted its holdings in shares of argenx by 0.3% in the first quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock valued at $487,609,000 after buying an additional 3,900 shares during the period. Clearbridge Investments LLC lifted its holdings in shares of argenx by 3.6% in the second quarter. Clearbridge Investments LLC now owns 617,466 shares of the company’s stock valued at $265,535,000 after buying an additional 21,189 shares during the period. Finally, Sei Investments Co. lifted its holdings in shares of argenx by 15.2% in the second quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock valued at $164,079,000 after buying an additional 50,477 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Price Performance

Shares of ARGX stock opened at $564.23 on Friday. argenx SE has a fifty-two week low of $327.73 and a fifty-two week high of $611.22. The stock’s 50-day moving average is $552.89 and its two-hundred day moving average is $481.22. The firm has a market cap of $33.74 billion, a P/E ratio of -641.16 and a beta of 0.61.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same period in the prior year, the firm posted ($1.25) EPS. As a group, research analysts expect that argenx SE will post 2.2 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ARGX. Truist Financial upped their price objective on argenx from $540.00 to $660.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Guggenheim upped their price objective on argenx from $585.00 to $665.00 and gave the company a “buy” rating in a report on Friday, November 1st. Wells Fargo & Company upped their price objective on argenx from $547.00 to $639.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Oppenheimer upped their price objective on argenx from $560.00 to $646.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Finally, HC Wainwright upped their price objective on argenx from $533.00 to $617.00 and gave the company a “buy” rating in a report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $619.79.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.